- Trials with a EudraCT protocol (48)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
48 result(s) found for: Ophthalmoscopy.
Displaying page 1 of 3.
EudraCT Number: 2019-000804-14 | Sponsor Protocol Number: OPHT-070119 | Start Date*: 2019-05-10 |
Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology | ||
Full Title: The effect of hyperoxia and hypoxia on fluorescence lifetime imaging ophthalmoscopy in healthy subjects | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001119-19 | Sponsor Protocol Number: A0661206 | Start Date*: 2016-04-13 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: Ocular Effects Of Azithromycin Oral Solution In Pediatric Patients With Pharyngitis/tonsillitis | ||||||||||||||||||
Medical condition: pharyngitis/tonsillitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003415-22 | Sponsor Protocol Number: AP-W-CLI-2018-8 | Start Date*: 2019-03-22 | |||||||||||
Sponsor Name:Aurealis Oy | |||||||||||||
Full Title: A Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of single and repeated doses of AUP1602-C as topical treatment of diabetic foot ulcers | |||||||||||||
Medical condition: Diabetic foot ulcers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001121-10 | Sponsor Protocol Number: NS2330-004 | Start Date*: 2007-05-10 | |||||||||||
Sponsor Name:NeuroSearch A/S | |||||||||||||
Full Title: Evaluation of long term safety of tesofensine in patients with obesety. | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001421-55 | Sponsor Protocol Number: CRFB002GFR02 | Start Date*: 2013-06-13 | |||||||||||
Sponsor Name:Novartis Pharma S.A.S | |||||||||||||
Full Title: An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. | |||||||||||||
Medical condition: Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Ret... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002523-28 | Sponsor Protocol Number: KHAK1001 | Start Date*: 2016-09-16 | |||||||||||
Sponsor Name:Moorfields Eye Hospital | |||||||||||||
Full Title: A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa | |||||||||||||
Medical condition: Retinitis Pigmetosa. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002574-29 | Sponsor Protocol Number: 77550 | Start Date*: 2005-08-02 |
Sponsor Name:Santen Oy | ||
Full Title: Pharmacodynamics of tafluprost 0.0015% eye drops: a comparison between the preserved and unpreserved formulation in patients with open-angle glaucoma or ocular hypertension. | ||
Medical condition: Open angle glaucoma or ocular hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005542-35 | Sponsor Protocol Number: CRFB002DDE21 | Start Date*: 2012-05-08 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation ... | |||||||||||||
Medical condition: Proliferative diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012609-20 | Sponsor Protocol Number: 343/09 | Start Date*: 2009-09-08 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: INTRAVITREAL BEVACIZUMAB INJECTION VS. CONVENTIONAL LASER SURGERY FOR VISION-THREATENING RETINOPATHY OF PREMATURITY. | |||||||||||||
Medical condition: AP-ROP | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004271-12 | Sponsor Protocol Number: NGF0213 | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:Dompé s.p.a | |||||||||||||
Full Title: An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye | |||||||||||||
Medical condition: Dry Eye syndrome is caused by either decreased tear production or increased tear film evaporation. Dry eye is a chronic inflammatory condition of the ocular surface with severe symptoms and visual ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001019-30 | Sponsor Protocol Number: CRFB002EDE17 | Start Date*: 2011-06-01 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal imp... | |||||||||||||
Medical condition: visual impairment due to macular edema following branch retinal vein occlusion (BRVO) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002947-27 | Sponsor Protocol Number: SYL040012_IV | Start Date*: 2014-07-01 | |||||||||||
Sponsor Name:Sylentis S.A.U. | |||||||||||||
Full Title: A phase II, observer masked, active controlled study of SYL040012 for the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension (SYLTAG) | |||||||||||||
Medical condition: Open angle glaucoma - intraocular pressure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005160-18 | Sponsor Protocol Number: RP101-200 | Start Date*: 2018-12-18 | |||||||||||
Sponsor Name:Redwood Pharma AB | |||||||||||||
Full Title: A Phase II, multicentre, randomised, placebo-controlled, double-masked trial of RP101 ophthalmic formulation versus vehicle in post-menopausal women with moderate to severe dry eye syndrome | |||||||||||||
Medical condition: moderate or severe dry eye syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004775-13 | Sponsor Protocol Number: SYD-101-001 | Start Date*: 2019-08-02 | |||||||||||
Sponsor Name:Sydnexis, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children | |||||||||||||
Medical condition: Myopia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016196-29 | Sponsor Protocol Number: M11-327 | Start Date*: 2010-07-19 | |||||||||||||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||||||||||||
Full Title: A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate-, Posterior-, or Pan-uveitis | |||||||||||||||||||||||
Medical condition: Non-infectious Intermediate-, Posterior-, or Pan-uveitis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002109-20 | Sponsor Protocol Number: AAV2-hRPE65v2-301 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:Spark Therapeutics, Inc. | |||||||||||||
Full Title: A Safety and Efficacy Study in Subjects with Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-h... | |||||||||||||
Medical condition: Leber Congenital Amaurosis (LCA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004302-26 | Sponsor Protocol Number: 201350 | Start Date*: 2014-09-05 | |||||||||||
Sponsor Name:Santen Oy | |||||||||||||
Full Title: A phase I study to evaluate the pharmacokinetics, safety and tolerability of preservative free tafluprost ophthalmic solution (0.0015%) in pediatric patients diagnosed with glaucoma or ocular hyper... | |||||||||||||
Medical condition: Glaucoma or Ocular Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003334-33 | Sponsor Protocol Number: CRFB002FIT01 | Start Date*: 2013-12-16 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A 12-month, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal ... | |||||||||||||
Medical condition: Choroidal neovascularization secondary to pathologic myopia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001487-37 | Sponsor Protocol Number: 190342-032D | Start Date*: 2008-11-05 |
Sponsor Name:Allergan Limited | ||
Full Title: A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Br... | ||
Medical condition: Geographic Atrophy from Age-related Macular Degeneration | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) PT (Completed) IT (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-015586-31 | Sponsor Protocol Number: 190342-031D | Start Date*: 2010-01-29 | |||||||||||
Sponsor Name:Allergan Limited | |||||||||||||
Full Title: A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 3 Month Study with a 9-Month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug ... | |||||||||||||
Medical condition: Rhegmatogenous Macula-off Retinal Detachment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
